All In Biotech

Drug Trial Radar · NCT00865969

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

129

Actual

Start

Dec 15, 2008

Primary completion

Nov 5, 2013

Study completion Oct 27, 2014

Sponsor

Lead sponsor
Spectrum Pharmaceuticals, IncIndustry
Sponsor type
Industry
Collaborators
Valerio Therapeutics
First posted
Mar 20, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy and safety of belinostat in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL), who failed at least one prior systemic therapy.

Conditions

  • Peripheral T-cell Lymphoma

Interventions

  • BelinostatDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: 24 months

Locations

117 sites in 17 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • Wilshire Oncology Medical Group, Inc

    La Verne, California

  • Comprehensive Cancer Center

    Palm Springs, California

  • Yale Cancer Center-Section of Medical Oncology

    New Haven, Connecticut

  • Oncology Associates of Bridgeport

    Trumbull, Connecticut

  • Boca Raton Clinical Research Associates

    Boca Raton, Florida

  • Georgia Health Sciences University

    Augusta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Kellogg Cancer Care Center

    Evanston, Illinois

  • Illinois Cancer Specialists/Cancer Care & Hematology Specialists of Chicagoland

    Niles, Illinois

  • Illinois CancerCare, P.C.

    Peoria, Illinois

  • Center for Cancers and Blood Disorders

    Bethesda, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Boston University Medical Center

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Saint Louis University

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Northern New Jersey Cancer Associates

    Hackensack, New Jersey

  • Morristown Memorial Hospital

    Morristown, New Jersey

  • Erie County Medical Center (Roswell Park)

    Buffalo, New York

  • Monter Cancer Center

    Lake Success, New York

  • New York University Cancer Institute

    New York, New York

  • New York University

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Upstate Medical Univeristy Syracuse

    Syracuse, New York

  • Bronx River Medical Associates, PC

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Hematology Associates

    Bedford, Ohio

  • St Luke's Cancer Center

    Bethlehem, Pennsylvania

  • Penn State Hershey Cancer Institute

    Hershey, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Avera Cancer Center

    Sioux Falls, South Dakota

  • Associates In Oncology and Hematology

    Chattanooga, Tennessee

  • University of Tennessee Cancer Institute

    Knoxville, Tennessee

  • Accelerated Community Oncology Reseaerch Network, Inc. (ACORN)

    Memphis, Tennessee

  • UT - M. D. Anderson Cancer Center

    Houston, Texas

  • The UT Health Science Centre at San Antonio

    San Antonio, Texas

  • Massey Cancer Center

    Richmond, Virginia

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.